FinHER Regimen: Neoadjuvant Treatment Outcomes for HER2-Positive Breast Cancer

A retrospective audit of 100 patients with HER2-positive breast cancer treated with the neoadjuvant FinHer regimen in a resource-limited setting. The dataset likely contains patient-level clinical outcomes, including pathological complete response rates and survival metrics. It was authored by Anoop T. M. and last updated in May 2026.

Use Cases

• Analyze predictors of pathological complete response based on hormone receptor status.
• Model disease-free survival outcomes based on disease stage.
• Compare survival outcomes between stage III and oligometastatic patient cohorts.
• Investigate the association between HER2-enriched subtype and treatment response.

Strengths

• Contains results for 100 patients, providing a specific cohort size.
• Reports a pathological complete response rate of 30%, a concrete outcome metric.
• Includes statistically significant associations (e.g., p=0.002 for ER/PR positivity and pCR).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the South Indian population studied.

Provenance

Source

figshare

Collection Method

Retrospective audit of patient records.

Freshness

Last updated 2026-05-18 04:10:40; freshness should be verified.

Geography

South Indian population